Development of cGMP packaging cell lines for retro & lentivirus production using innovative molecular engineering strategies

最近在治疗一系列自身免疫性疾病和癌症方面的进展需要越来越复杂的医学解决方案。一种迅速扩大的非常成功的治疗方法是将DNA输送到人类细胞(基因疗法)，为它们提供新的特征和特性来帮助抗击疾病。实现这一点的一种高效方法是使用修饰的病毒，如慢病毒，来传递DNA。然而，制造慢病毒的过程效率非常低，因为还没有制造出能够有效包装病毒的细胞。这样做的原因是，完成这一任务所需的一些基因对细胞有毒性。我们最近针对这一问题开发了一种新的解决方案，并已经产生了高效生产慢病毒的第一代细胞系。我们现在的目标是开发这种细胞系的临床级别版本，并创造一系列更深入、更先进的细胞系，以改进慢病毒的生产。

Recent advances in the treatment of a range of autoimmune diseases and cancer have requiredincreasingly complex medical solutions. One rapidly expanding range of very successful treatments isthe delivery of DNA to human cells (gene therapy) to provide them with new features and propertiesto help fight disease. A highly efficient method of achieving this is to use modified viruses, such aslentiviruses, to deliver the DNA. However, the process of making lentiviruses is highly inefficientbecause no cells have yet been made that allow the virus to be packaged efficiently. The reason forthis is that some of the genes required to do this are toxic to the cell. We have recently developed anovel solution to this problem, and have already generated a first generation cell line that produceslentiviruses highly efficiently. We now aim to develop clinical grade versions of this cell line andcreate a series of further, more advanced, cell lines for improved lentivirus production.